Acalabrutinib in management of chronic lymphocytic leukemia: An Indian perspective
Abstract The treatment landscape of chronic lymphocytic leukemia (CLL) has witnessed immense changes in the past decade. Several newer target therapies and their combinations with anti‐CD 20 therapies have got approval for management of CLL in the treatment‐naïve and relapsed/refractory setting. Als...
Tallennettuna:
| Päätekijät: | , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Wiley
2021-08-01
|
| Sarja: | eJHaem |
| Linkit: | https://doi.org/10.1002/jha2.227 |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|